Apellis' EMPAVELI: First Treatment for Rare Kidney Diseases
FDA-approved EMPAVELI (pegcetacoplan) for C3G & IC-MPGN in patients 12+. Shows 68% proteinuria reduction, kidney function stabilization, and C3 deposit clearance. A transformational therapy for 5,000 US patients.
This post is for paying subscribers only
Already have an account? Sign in.